Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is one of the best mid-cap growth stocks to buy right now. On January 13, Baird analyst Brian Skorney raised the firm’s price target on Mirum Pharmaceuticals to $95 from $81, while maintaining an Outperform rating. This revision came as the firm updated its valuation model after preliminary results delivered a beat-and-raise on earnings and guidance. The stronger-than-expected data provides a solid foundation heading into a high-activity year in 2026.
Furthermore, H.C. Wainwright raised its price target for Mirum Pharmaceuticals to $102 from $81 and maintained a Buy rating. The firm described the company’s preliminary financial results as impressive and noted bullish guidance for 2026.
Earlier on December 19, Citizens raised the price target for Mirum Pharmaceuticals Inc. to $140 from $95 with an Outperform rating. The firm noted that Mirum has outperformed year-to-date and is expected to maintain its leadership position in 2026, fueled by several high-confidence pivotal readouts within its clinical pipeline.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes novel therapies for debilitating rare and orphan diseases.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
